Itacitinib (** Generic only (investigational - not yet FDA approved for marketing) **)

Description

Itacitinib is an investigational drug currently being studied in clinical trials for various advanced solid tumors, including some types of colorectal cancer (specifically MSI-high or MMR-deficient tumors). It is a type of targeted therapy. The trials are in early phases (Phase 1), meaning they are primarily focused on determining the right dose and assessing safety, rather than proving effectiveness. Itacitinib is being tested in combination with pembrolizumab (an immunotherapy drug) in these trials. The trials are looking at patients who may have specific genetic changes (like ALK mutations/fusions, EGFR mutations, KRAS mutations, or PD-L1 expression) or who have not responded to previous treatments. Itacitinib is not yet approved by the FDA for treating colorectal cancer or any other condition.

Mechanism of Action

Itacitinib is a targeted therapy that works by inhibiting JAK1, a specific protein involved in signaling pathways within cells. These pathways can play a role in tumor growth and survival. By blocking JAK1, itacitinib aims to disrupt these signals and potentially slow or stop the growth of cancer cells. The specific role of JAK1 inhibition in colorectal cancer and the effectiveness of itacitinib are still being investigated in clinical trials.

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials